Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

T. E. Coyle, M. T. Reding, J. C. Lin, L. A. Michaels, A. Shah, J. Powell

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A'. Together they form a unique fingerprint.

Medicine & Life Sciences